Alterity Therapeutics Limited (ASX: ATH)
Health Care · Biotechnology · AU
AU$0.49
-10.09% today · -18.3% 1Y
Alterity Therapeutics Limited (ASX: ATH) operates in the Biotechnology industry within the Health Care sector. The company is valued at $76.40M and employs 9 people.
Over the last twelve months the share price has lost 18.3%, trading between 0.35 and 0.79.
Tweenvest scores Alterity Therapeutics Limited across four factors: quality 40/100, value 59/100. Its strongest factor is value.
ATH price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $76.40M
- Revenue (TTM)
- $4.43M
- P/E
- —
- EPS
- -0.08
- Dividend yield
- —
- Beta (5Y)
- -0.04
- 52-week high
- AU$0.79
- 52-week low
- AU$0.35
- Avg volume (3M)
- —
- Shares outstanding
- 217.51M
- Employees
- 9
- Next earnings
- —
About Alterity Therapeutics Limited
Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997, is dedicated to the discovery and advancement of treatments for neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases, among others. The company's primary drug candidate, ATH434, has successfully navigated Phase I clinical trials for Parkinson's disease. Additionally, it is progressing PBT2, an investigational compound for Alzheimer's disease that has completed Phase 2a clinical trials. The firm, previously known as Prana Biotechnology Limited, adopted its current name, Alterity Therapeutics Limited, in April 2019.
- ISIN
- AU0000043945
- Founded
- 1997
- Listed since
- Mar 28, 2000
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.